23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change today | 1-month return | 1-year return | Total return |
---|---|---|---|---|
The fight against COVID19 | +1.12% | - | - | - |
^GSPC | +1.17% | +5.08% | +29.15% | +5607.69% |
Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 152.67 | +1.29 | +0.85% | 16:00 GMT-4 | 5.37M | 7.47M | 367.43B |
ABBV | AbbVie Inc. | 163.79 | +2.20 | +1.36% | 16:00 GMT-4 | 5.26M | 5.64M | 289.23B |
PFE | Pfizer Inc. | 28.82 | +0.44 | +1.55% | 16:01 GMT-4 | 34.60M | 42.78M | 163.31B |
SNY | Sanofi | 49.01 | -0.49 | -0.99% | 16:00 GMT-4 | 4.25M | 2.01M | 123.66B |
REGN | Regeneron Pharmaceuticals, Inc. | 978.21 | -6.43 | -0.65% | 16:00 GMT-4 | 590.22k | 457.32k | 107.79B |
GSK | GlaxoSmithKline plc | 45.7 | +0.04 | +0.09% | 16:00 GMT-4 | 3.77M | 3.15M | 94.23B |
GILD | Gilead Sciences, Inc. | 67.01 | -0.64 | -0.95% | 16:00 GMT-4 | 7.53M | 7.06M | 83.48B |
MRNA | Moderna, Inc. | 129.06 | +0.74 | +0.58% | 16:00 GMT-4 | 2.94M | 3.85M | 49.46B |
TAK | Takeda Pharmaceutical Company Limited | 13.39 | -0.06 | -0.45% | 16:00 GMT-4 | 1.10M | 1.67M | 42.02B |
BNTX | BioNTech SE | 92.2 | -0.08 | -0.09% | 16:00 GMT-4 | 467.64k | 596.34k | 22.22B |
NVAX | Novavax, Inc. | 12.9 | -0.58 | -4.30% | 16:00 GMT-4 | 24.39M | 12.56M | 1.90B |
VIR | Vir Biotechnology, Inc. | 10.02 | -0.06 | -0.60% | 16:00 GMT-4 | 717.88k | 1.00M | 1.36B |
INO | Inovio Pharmaceuticals, Inc. | 13.07 | +1.65 | +14.45% | 16:00 GMT-4 | 731.54k | 445.47k | 338.60M |
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 – – At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI: 8.1-NR) – – Across all vepdegestrant d
The TAK-003 vaccine targets all four virus serotypes.
Japan GDP shrank at an annualised rate of 2% in the January to March period, compared to the previous quarter,